Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial.

Front Immunol · 2025 · PMC12698628 · PMID 41394817

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Discussion In this single-center randomized controlled trial evaluating patients with incomplete immune reconstitution early after HSCT, CCP administration showed a trend toward delaying the time to COVID-19 infection but did not significantly reduce the cumulative incidence within one month after the last CCP infusion.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.